IDEXX Laboratories announces second quarter 2026 financial results
Revenue grew 10% as reported and 9% organic to $1.22 billion; EPS rose 18% to $4.27; the company raised its full-year guidance.
See the latest news and media coverage for IDEXX. We track all announcements, press releases, and industry mentions in real time, all in one place.
Veterinary diagnostics and animal health technology company
idexx.comLast updated
In short: IDEXX reported strong revenue growth and raised its 2026 outlook while announcing that Michael Erickson will succeed Jay Mazelsky as CEO.
Revenue grew 10% as reported and 9% organic to $1.22 billion; EPS rose 18% to $4.27; the company raised its full-year guidance.
The report highlights progress on innovation, people, and environmental goals, including GHG emission reductions and access to care.
The expansion adds detection of Taenia and Echinococcus species, broadening intestinal parasite screening in routine care.
Reports 14% revenue growth to $1,141 million, EPS of $3.47 up 17%, and raises full-year guidance.
IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing...
In other recent developments, IDEXX Laboratories reported second-quarter earnings that beat Wall Street expectations, driven by increased demand for diagnostics, improved...
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international...
IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.
Track IDEXX and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.